SUMMARY: Acute lymphoblastic leukemia (ALL) is early childhood hematological malignancies. In
present scenario immunophenotyping became an important tool for subtyping of ALL into B-ALL and TALL. In order to understand the mechanism of development of leukemia it is important to study the cytokine environment of
malignant cells.
OBJECTIVE: Aim of the present study was to evaluate clinical and hematological features in ALL and correlate serum levels of
IL6 and IL-10 expression in ALL patients and their subtypes.
MATERIALS & METHODS: A total of 68 ALL cases along with 20 healthy controls were included in the study between periods of
2015 to 2017. About 4 mL blood samples were collected from all cases for immunophenotyping and serum studies. Levels of IL6
and IL10 were determined in all cases by ELISA.
RESULT: In the present study immunphenotyping was done in all cases of ALL, which showed 52 cases (76.5%) of B-ALL and 16
cases (23.5%) of T-ALL. T-ALL was mostly found in higher aged children than B-ALL. A male predominance was seen in all
cases. No signicant differences in hemoglobin levels and platelet counts were found between T-ALL and B-ALL. A signicantly
high percentage of T-ALL cases were having more than 50000 cells per microliter than B-ALL (56.2% vs. 23.1%). Almost similar
clinical features were found in both subgroups, only bleeding manifestation was found signicantly higher in T-ALL than B-ALL
(31.2% vs.11.5%). Acute lymphoblastic leukemia (ALL) patients were associated with signicantly elevated serum IL6 and IL10 level than the healthy control group. Mean levels of serum IL6 were 167.9±306.46 pg/mL in ALL, and 6.51 ± 2.27 pg/mL in
healthy control group. Mean IL10 levels were 70.56±111.48 pg/mL in ALL and 29.39 ± 4.27 pg/mL in control group. There were
no signicant differences found in IL-6 and IL-10 serum levels between T-ALL and B-ALL.
CONCLUSION: Present study found elevated level of IL-6 and IL-10 in ALL patients which suggest possible role of these
cytokines in disease transformation. Detection of IL-6 and IL-10 in newly diagnosed patient may predict disease outcome and
possibly poor prognosis in patients